Advertisement

Topics

Novartis: Sandoz Proposed Biosimilar Adalimumab Matches Reference Biologic

02:00 EDT 14 Sep 2017 | FinanzNachrichten

BASEL (dpa-AFX) - Swiss drug giant Novartis (NVS) announced Thursday that Sandoz proposed biosimilar adalimumab matched reference biologic in terms of efficacy and safety in long-term study.ADACCE...

Original Article: Novartis: Sandoz Proposed Biosimilar Adalimumab Matches Reference Biologic

NEXT ARTICLE

More From BioPortfolio on "Novartis: Sandoz Proposed Biosimilar Adalimumab Matches Reference Biologic"

Quick Search
Advertisement
 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...